Future studies should prioritize defining the patient subgroups most likely to benefit from GLP-1 RA therapy, exploring synergistic effects with existing HF therapies, and investigating the mechanistic underpinnings of their cardiac actions, particularly in HFrEF and non-obese HF phenotypes. The gene discussed is GLP1R; the disease is hydrops fetalis.